1nhaler raises £2.2M in funding led by Archangels to advance its lead product, 1nhaler Salbutamol, and support late-stage development.
PRIVATENov 03, 2026
Amount Raised
£2.2 Million
Round Type
Seed
EdinburghManufacturingBiotechnology
Investors
BBB InvestmentsScottish EnterpriseArchangels
Description
1nhaler, a drug delivery device developer from Edinburgh, raised £2.2M in funding. The round was led by Archangels, with participation from Scottish Enterprise and BBB Investments. This funding will facilitate late-stage development of its lead product and support clinical trials. Founded by Don Smith, 1nhaler focuses on innovative inhalation solutions for various medical conditions.
Who to call at 1nhaler, and when
A new round usually means 1nhaler is about to hire and buy. The teams that reach out first get the meeting.
An alert the day 1nhaler raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at 1nhaler, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at 1nhaler. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
1nhaler
Location
Edinburgh, Scotland, United Kingdom
About
1nhaler is developing a single-dose dry-powder inhaler that is simple to use, low-cost, and compact enough to fit in a wallet. Propellant-free and made primarily from cardboard, the device transforms from a flat, credit-card form into a functional three-dimensional inhaler. Its patent-protected membrane dispersion technology supports a wide range of medicines in dry-powder format. Designed to be lightweight, affordable, and easy to deploy, 1nhaler aims to unlock the full potential of inhalable dry powders and extend life-saving treatments to more people worldwide.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment 1nhaler raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
EdinburghManufacturingBiotechnology